The Indian government has approved the inclusion of weight-loss drugs Mounjaro and Ozempic under the Central Government Health Scheme (CGHS) for eligible beneficiaries.
Authorities have issued strict warnings against the misuse of these medications, emphasizing that they must only be prescribed for clinically diagnosed obesity and diabetes.
The move aims to provide affordable access to advanced weight-management therapies while implementing monitoring protocols to prevent unauthorized distribution and rule violations.